{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260629189605/en/Zura-Bio-Exceeds-Enrollment-Target-in-Both-Hidradenitis-Suppurativa-HS-Systemic-Sclerosis-SSc-Phase-2-Studies-and-Expands-Tibulizumab-Program", "message": "News view counter 820300 successfully enlarged"}